Alnylam And Silence Settle Over RNAi Patents

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.

breadcrumbs on empty plate
Settlement will give Silence a few crumbs from Alnylam's Onpattro sales • Source: Shutterstock

The UK’s Silence Therapeutics PLC and Alnylam Pharmaceuticals Inc. have agreed to settle litigation in which the former accused the latter of infringing its European patents.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Business